Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study

OBJECTIVE: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC). Several studies suggest antiseizure effects also beyond these three epilepsy syndromes. METHODS: In a retrospective multicenter study, we analyzed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühne, Fabienne, Becker, Lena‐Luise, Bast, Thomas, Bertsche, Astrid, Borggraefe, Ingo, Boßelmann, Christian Malte, Fahrbach, Jörg, Hertzberg, Christoph, Herz, Nina A., Hirsch, Martin, Holtkamp, Martin, Janello, Christine, Kluger, Gerhard Josef, Kurlemann, Gerhard, Lerche, Holger, Makridis, Konstantin L., von Podewils, Felix, Pringsheim, Milka, Schubert‐Bast, Susanne, Schulz, Juliane, Schulze‐Bonhage, Andreas, Steinbart, David, Steinhoff, Bernhard J., Strzelczyk, Adam, Syrbe, Steffen, De Vries, Heike, Wagner, Christiane, Wagner, Johanna, Wilken, Bernd, Prager, Christine, Klotz, Kerstin A., Kaindl, Angela M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235575/
https://www.ncbi.nlm.nih.gov/pubmed/36693811
http://dx.doi.org/10.1002/epi4.12699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235575/
https://www.ncbi.nlm.nih.gov/pubmed/36693811
http://dx.doi.org/10.1002/epi4.12699

Ejemplares similares